top of page
Previous Item

DNA

BRAF

ERCC2

FGFR1

FGFR2

FGFR3

MTOR

NTRK1

NTRK3

SMAD4

FBXW7

TP53

FUSION

FGFR2 Fusion

FGFR3 Fusion

NTRK1 Fusion

NTRK2 Fusion

NTRK3 Fusion

RET Fusion

MET Fusion

PD-L1 IHC

Microsatellite Instability (MSI)


Method: Next Generation Sequencing (NGS)

Sample Type: Tissue, Blood (Liquid Biopsy Tube)

Result Time: 20-25 Days

Sensitivity: 99%

Description: 11 Gen - 7 Fusion + MSI + PD-L1 IHC


BLADDER PLUS PANEL

✓ Paraffin Block ✓ Liquid Biopsy

BLADDER PLUS PANEL

Bladder cancer has recently become one of the cancer types with significant advances in studies with newly developed drugs. Comprehensive genetic analysis, especially FGFR fusion, is recommended for eligibility for smart therapies after first-line treatment. In addition, PDL1 analysis can be very guiding in determining the decision of Adjuvant Immunotherapy in early stage bladder cancer.


bottom of page